Tempo Therapeutics

Tempo Therapeutics is a late development stage therapeutic device company creating innovative material science solutions for tissue engineering in regenerative medicine, beginning with complex wounds; a multi-billion dollar market opportunity, and extending into cardiac, neural, and orthopedic indications with huge unmet needs. Our technology can build new functional tissue in these indications and transform patient care. Current tissue engineering technologies cannot meet patient needs, because these implants are rejected by the patient's immune system, and are unable to build new tissue and restore organ function. Tempo meets this critical unmet need with our patent-protected MAP biomaterial technology. MAP enables fully-synthetic injectable implants that, through critical immune privilege, build NEW tissue within patients, in real time - without the need for delivery of any biologics or cells. MAP empowers patient biology to build tissue within our synthetic materials - recognized by immune cells as 'self' and avoiding the foreign body response that limits the efficacy of all other current and emerging technologies in tissue engineering. Since beginning operations in mid 2016, Tempo has achieved the following important milestones- significantly de-risking the company and providing a clear path to market: • Winning over $1.7M in non-diluting grant funding from the NIH • Submitting our first product, TT101, to FDA for approval as a medical device • Receiving awarded patents covering composition, manufacturing, and methods of use • Building a scaled and cGMP-ready manufacturing process • Treating >20 real-world cases of complex wounds in veterinary medicine with 100% success • Completing independent animal study validations of TT101 with potential corporate partners • Innovative R&D efforts to expand our patent portfolio and pipeline indications beyond complex wounds to medical aesthetics, orthopedics, cardiac, and vaccine technology. Our initial success with TT101 de-risks regulatory activity, a partnership development model, and will enable a fast path to revenue to increase company value. Tempo's unique MAP technology provides opportunity in many therapeutic areas including tissue atrophy and medical aesthetics - multi-billion dollar markets in which Tempo has already developed candidates. Further, our technology reaches even broader into high growth therapeutic areas including neural repair, cardiac repair, cell therapy, vaccine technology, and drug delivery.